A novel 5′ ATRX mutation with splicing consequences in acquired α thalassemia-myelodysplastic syndrome

Haematologica

Volumn 90, Issue 11, 2005, Pages 1463-1470

  Nelson, Maria E ^a,b   Thurmes, Paul J ^a   Hoyer, James D ^a   Steensma, David P ^a,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c Mayo Clinic   (United States)

Author keywords

thalassemia; Acquired hemoglobinopathy; Myelodysplastic syndrome; Splicing

Indexed keywords

ALPHA GLOBIN; COMPLEMENTARY DNA; CORTICOSTEROID; DICLOFENAC; ERYTHROPOIETIN; PLASMID VECTOR; PREDNISONE; STEROID; ATRX PROTEIN, HUMAN; HELICASE; NUCLEAR PROTEIN;

5' UNTRANSLATED REGION; ACHILLES TENDON; ADULT; ALPHA THALASSEMIA; ALTERNATIVE RNA SPLICING; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW; BONE MARROW CELL; CASE REPORT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CLONAL VARIATION; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EXON; FRAMESHIFT MUTATION; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INTRON; IRIDOCYCLITIS; IRON DEFICIENCY ANEMIA; KARYOTYPE; LABORATORY TEST; MALE; MICROCYTIC ANEMIA; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN MOTIF; RESTRICTION MAPPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; STOP CODON; TENDINITIS; DNA FLANKING REGION; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; RNA SPLICING;

5' FLANKING REGION; ALPHA-THALASSEMIA; BASE SEQUENCE; DNA HELICASES; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; POINT MUTATION; RNA SPLICE SITES;

EID: 27844524061     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-60.
2. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003;27:95-120.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
4. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998;22:871-8.
5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17: 3835-49.
6. Higgs DR, Wood WG, Barton C, Weatherall DJ. Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med 1983;75:181-91.
7. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005;105:443-52.
8. Weatherall DJ, Clegg JB. The thalassaemia syndromes. Oxford: Blackwell. 2001.
9. Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, et al. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the α-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet 2003;34:446-9.
10. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with α thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004;103:2019-26.
11. Steensma DP, Viprakasit V, Hendrick A, Goff DK, Leach J, Gibbons RJ, et al. Deletion of the α-globin gene cluster as a cause of acquired α-thalassemia in myelodysplastic syndrome. Blood 2004;103: 1518-20.
12. Gibbons RJ, Wilkie AO, Weatherall DJ, Higgs DR. A newly defined X linked mental retardation syndrome associated with α thalassaemia. J Med Genet 1991; 28:729-33.
13. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome). Cell 1995;80:837-45.
14. Gibbons RJ, Higgs DR. Molecular-clinical spectrum of the ATR-X syndrome. Am J Med Genet 2000;97:204-12.
15. Gibbons RJ, McDowell TL, Raman S, O'Rourke DM, Garrick D, Ayyub H, et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet 2000;24:368-71.
16. Gibbons RJ, Bachoo S, Picketts DJ, Aftimos S, Asenbauer B, Bergoffen J, et al. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat Genet 1997;17:146-8.
17. Higgs DR. Ham-Wasserman lecture: gene regulation in hematopoiesis: new lessons from thalassemia. Hematology Am Soc Hematol Educ Program 2004;3: 1-13.
18. Picketts DJ, Tastan AO, Higgs DR, Gibbons RJ. Comparison of the human and murine ATRX gene identifies highly conserved, functionally important domains. Mamm Genome 1998;9:400-3.
19. Steensma DP, Allen S, Gibbons RJ, Fisher CA, Higgs DR. A novel splicing mutation in the gene encoding the chromatin-associated factor ATRX associated with acquired hemoglobin H disease in myelodysplastic syndrome (ATMDS). [Abstract 3606]. In: American Society of Hematology; 2004; San Diego. 2004.
20. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003;17:419-37.
23. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004;22:535-46.
24. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005; 42:342-57.
25. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64: 7647-54.
26. Kole R, Vacek M, Williams T. Modification of alternative splicing by antisense therapeutics. Oligonucleotides 2004;14: 65-74
27. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002;277:49374-82.
28. Tazi J, Durand S, Jeanteur P. The spliceosome: a novel multi-faceted target for therapy. Trends Biochem Sci 2005; 30:469-78.
29. Pergolizzi RG, Crystal RG. Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. C R Biol 2004;327:695-709.
30. Peres Lopes GM, de Souza SJ. Dissecting the human spliceosome through bioinformatics and proteomics approaches. J Bioinform Comput Biol 2004;1:743-50.
31. Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 2003;12:5-14.
32. Park JW, Parisky K, Celotto AM, Reenan RA, Graveley BR. Identification of alternative splicing regulators by RNA interference in Drosophila. Proc Natl Acad Sci USA 2004;101:15974-9.
33. Lee DW, Zhang K, Ning ZQ, Raabe EH, Tintner S, Wieland R, et al. Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia. Cancer Res 2000;60:3612-22.
34. Yano M, Ouchida M, Shigematsu H, Tanaka N, Ichimura K, Kobayashi K, et al. Tumor-specific exon creation of the HELLS/SMARCA6 gene in non-small cell lung cancer. Int J Cancer 2004;112:8-13.
35. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302: 2141-4.
36. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005;6:386-98.
37. Ast G. The alternative genome. Sci Am 2005;292:40-7.
38. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, et al. Function of alternative splicing. Gene 2005;344:1-20.
39. Conti E, Izaurralde E. Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol 2005;17:316-25.
40. Garrick D, Samara V, McDowell TX, Smith AJ, Dobbie L, Higgs DR, et al. A conserved truncated isoform of the ATR-X syndrome protein lacking the SWI/SNF-homology domain. Gene 2004; 326:23-34.
41. Picketts DJ, Higgs DR, Bachoo S, Blake DJ, Quarrell OW, Gibbons RJ. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 1996;5:1899-907.
42. Villard L, Lossi AM, Cardoso C, Proud V, Chiaroni P, Colleaux L, et al. Determination of the genomic structure of the XNP/ATRX gene encoding a potential zinc finger helicase. Genomics 1997;43: 149-55.
43. Gibbons RJ, Wada T. ATRX and X-linked [α]-thalassemia mental retardation syndrome. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, eds. Inborn Errors of Development. Oxford: Oxford University Press; 2004. p. 747-57.
44. Fichera M, Silengo M, Spalletta A, Giudice ML, Romano C, Ragusa A. Prenatal diagnosis of ATR-X syndrome in a fetus with a new G→T splicing mutation in the XNP/ATR-X gene. Prenat Diagn 2001;21:747-51.
45. Villard L, Toutain A, Lossi AM, Gecz J, Houdayer C, Moraine C, et al. Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without α-thalassemia. Am J Hum Genet 1996;58:499-505.
46. Gruss P, Khoury G. Rescue of a splicing defective mutant by insertion of an heterologous intron. Nature 1980;286:634-7.
47. Abidi FE, Cardoso C, Lossi AM, Lowry RB, Depetris D, Mattei MG, et al. Mutation in the 5′ alternatively spliced region of the XNP/ATR-X gene causes Chudley-Lowry syndrome. Eur J Hum Genet 2005;13:176-83.
48. Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997; 24:483-9.
49. Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002;43:2083-92.
50. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-63.
51. Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res 2003;27:235-42.
52. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005;80:681-98.
53. Cardoso C, Lutz Y, Mignon C, Compe E, Depetris D, Mattei MG, et al. ATR-X mutations cause impaired nuclear location and altered DNA binding properties of the XNP/ATR-X protein. J Med Genet 2000;37:746-51.